HANSA BIOPHARMA

Interim Results Jan - June 2025

July 17, 2025



Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

Q2 2025 Results Conference Call Agenda

17 July 2025



CEO Remarks	Renée Aguiar-Lucander CEO
Operational Update	Maria Törnsén COO, President US
Pipeline Update	Hitto Kaufmann Chief Scientific & Technology Officer
Financial Results	Evan Ballantyne Chief Financial Officer
Close and Q&A	Renée Aguiar-Lucander CEO

Significant achievements in 1H 2025

Stabilized the Business

Extended cash runway to Q2 2026 through directed share issue and debt restructure

Bolstered leadership team with addition of Maria Törnsén, COO and President US and Dr. Richard Philipson, CMO

Strong growth in European revenues Q2 product sales represents 76% increase vs Q2 24 and 1H25 represents 52% increase vs 1H24

Advanced the Pipeline

Positive Ph 2 data in GBS demonstrated efficacy and safety of imlifidase; data presented at key medical congress

PAES enrolment complete and data readout on track for 2026 followed by EMA submission

Key gene therapy data on track for 2H 2025 Sarepta and Genethon to report out data

Strong product sales growth in 1H 2025

Quarterly Product Sales

76% increase as compared to Q2 2024



1H Product Sales

52% increase as compared to 1H 2024



1H Product Sales

80% of FY 2024 revenue



**All numbers reflected in MSEK*

Current financial snapshot

Directed Share Issue

- Successful capital raise of 232 MSEK
- Proceeds will help complete two ongoing phase III trials for imlifidase, EU commercialization, general headcount and operating expenses
- Will take the company through all key read outs into 2026

Nasdaq OMX Stockholm	HNSA
# of Shares Outstanding:	84.8 million
Market Cap:	2.22 BSEK (as of Jun 30th) ($233 million) @ 26.2 SEK (~$2.69) per share
Cash & Cash Equivalents:	354.4 MSEK (as of Jun 30th) ($37.1 million)

Debt and Restructuring Terms

- July 2022, the Company entered into a US $70.0 million funding agreement with NovaQuest

Revised Terms

- Offset $14.9M in debt with equity; addt't $14.9M of debt paid with equity or cash at Hansa's discretion in Jan 2026
- No additional payments until June 2027
- Repayment obligation - $150.5M (MOIC: 2.15)
- Final payments June 2027 through January 2029

Operational Overview and Strategic Review

Restructuring process completed in Q2 with expected annual cost savings of around SEK 60m

Simplified organisational structure for clarity, speed and transparency of decision-making

Strengthening of market research, systems and forecasting

Focus on cost efficiency, product USPs, skill and competency mapping

Strategic review initiated for follow on compound(s) and pipeline indications – Q4 target

Q2 2025 Results Conference Call Agenda

17 July 2025



CEO Remarks	Renée Aguiar-Lucander CEO
Operational Update	**Maria Törnsén** **COO, President US**
Pipeline Update	Hitto Kaufmann Chief Scientific & Technology Officer
Financial Results	Evan Ballantyne Chief Financial Officer
Close and Q&A	Renée Aguiar-Lucander CEO

Commercial momentum continues in Europe

Clinical Readiness

- 117 clinics are IDEFIRIX ready to treat
- 65% of PAES centers transitioned to commercial utilization
- 60% of clinics have used IDEFIRIX more than once

Patient Selection & Treatment

- 200+ local scientific events and global engagements
- 9 countries issued clinical guidelines
- 3 international consensus / guidance on desensitization

Market Access

- Reimbursement in 20 markets incl. largest EU markets
  **2 additional markets in Q2 2025*
- Access in more than 75% of EU transplant market

Kidney Transplantation represents a solid market opportunity and key learnings from Europe can be applied for the US market

Significant Unmet Need

- ~170,000 are waiting for a new kidney across Europe and US
- ~25,000 are highly sensitized (cPRA> 80%)
- ~5,000 patients have a cPRA>99.9%

Key Learnings from Europe

- Organ allocation system is not standardized across countries
- Clinical guidelines are critical for adoption and understanding of the appropriate patient for IDEFIRIX
- Clinical readiness involves multiple stakeholders within a hospital system
- Engagement with payors and national authorities takes time and is critical to secure reimbursement

US Focus

- Leverage US clinical data and EU real world experience
- Educate clinicians and multidisciplinary teams on desensitization, treatment guidelines and emerging data
- Payor/health policy engagement to highlight patient preference, improve kidney care and enable reimbursement and access at launch
- Patient group engagement to elucidate unmet needs and support change of standard of care

Calculated Panel Reactive Antibodies (cPRA) is a measure for HLA-sensitization

Q2 2025 Results Conference Call Agenda

17 July 2025



CEO Remarks	Renée Aguiar-Lucander CEO
Operational Update	Maria Törnsén COO, President US
Pipeline Update	**Hitto Kaufmann** **Chief Scientific & Technology Officer**
Financial Results	Evan Ballantyne Chief Financial Officer
Close and Q&A	Renée Aguiar-Lucander CEO

Focused pipeline in Desensitization and Autoimmune Diseases

	Preclinical	Phase 1	Phase 2	Phase 3	Marketed	Partner	Upcoming Milestone
idefirix (imlifidase)	Desensitization Kidney Transplantation						2026: EU Ph 3 PAES data read out
	Desensitization Kidney Transplantation						2H 2025: ConfIdeS US Phase 3 data read out
	Desensitization Gene Therapy (Crigler Najjar)					GENETHON	2025: GNT-018-IDES complete enrolment
	Desensitization Gene Therapy (DMD)					SAREPTA	2025: SRP-9001-104 data read out
	Desensitization Gene Therapy (LGMD)					SAREPTA	Preclinical Research
	Autoimmune GBS						2025:15-HMedIdeS-09 data publication
	Autoimmune anti-GBM						2025: GOOD-IDES-02 data read out
	Autoimmune ANCA (Investigator Initiated Trial)[1]						2025: Complete enrolment

[1] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charité Universitätsmedizin, Berlin, Germany

Phase 3 pivotal ConfIdeS trial data expected in 2H 2025

Study Overview

Open-label, controlled, randomized trial evaluating 12-month kidney function in highly sensitized kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care.

Primary Endpoint: Estimated glomerular filtration rate (eGFR)
Secondary Endpoint: Graft and patient survival parameters, antibody mediated rejection parameters, anti-drug antibody measures, imlifidase PK

Pre-screening

- Organ offer received via virtual crossmatch
- Key inclusion criteria: positive crossmatch against deceased donor

12-month Post Transplant Follow Up

All patients will receive:

- Induction therapy
- Maintenance immunosuppression

At 12-months:

- All patients will undergo a kidney biopsy

Trial Specifics

64 patients randomized
150 consented patients
23 participating sites

Key Centers and KOLs

- Robert Montgomery, NYU Langone
- Matt Cooper, Medical Center Wisconsin
- Osama Gaber, Houston Methodist Hospital

Catalysts and Timeline

- Randomization completed (May 2024)
- Topline data expected 2H 2025
- BLA submission in 2025

If approved in the US, imlifidase could enable kidney transplantation for 25,000 highly sensitized kidney transplant patients.*

*cPRA of 98% or higher

GOOD-IDES-02 Phase 3 Trial Top Line Data Expected in 2H 2025

Results from Phase 2 Study Results Published in JASN (2022)

10 out of 15 patients were dialysis independent after six months vs. the historical cohort, where only 18% had functioning kidney



Imlifidase granted orphan drug designation by US FDA and EMA

GOOD-IDES-03 Open Label Phase 3 Trial

- Fully enrolled 50 patients from 30+ centers in US, UK and EU
- Primary Endpoints: eGFR at 6 months and need for dialysis
- Secondary Endpoints: anti-GBM antibody levels, pulmonary symptoms, safety, PK/PD and health related quality of life
- 25 patients were randomized to receive imlifidase in combination with SOC and 25 patients received only SOC

SOC: Standard of Care consisting of a combination of immunosuppressives, glucocorticoids, and plasma exchange,

Ohlin et al. JASN (2022)
Journal of the American Society of Nephrology https://pubmed.ncbi.nlm.nih.gov/35260419/
McAdoo et al.: Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92: 693–702, 2017

Q2 2025 Results Conference Call Agenda

17 July 2025



CEO Remarks	Renée Aguiar-Lucander CEO
Operational Update	Maria Törnsén COO, President US
Pipeline Update	Hitto Kaufmann Chief Scientific & Technology Officer
Financial Results	**Evan Ballantyne** **Chief Financial Officer**
Close and Q&A	Renée Aguiar-Lucander CEO

Strong H1 2025 IDEFIRIX Sales Performance





*Contract revenue from agreements with Sarepta, AskBio & Axis-Shield





Continued investments in R&D and commercialization

SG&A Expenses (Q/Q)



*- SG&A expense w/out restructuring provision (21 MSEK) totals -70 MSEK

R&D Expenses (Q/Q)



*- R&D expense w/out restructuring provision (3 MSEK) totals -93 MSEK

Operating Loss (Q/Q)



*- Operating loss w/out restructuring provision (24 MSEK) totals -131 MSEK

SG&A Expenses (FY/FY)



*- SG&A expense w/out restructuring provision (21 MSEK) totals -146 MSEK

R&D Expenses (FY/FY)



*- R&D expense w/out restructuring provision (3 MSEK) totals -157 MSEK

Operating Loss (FY/FY)



*- Operating loss w/out restructuring provision (24 MSEK) totals -224 MSEK

Summary of Cash & Headcount

Operating Cash Flow (Q/Q)



Operating Cash Flow (FY/FY)



Cash & Cash Equivalents (Q/Q)



Number of Employees (Q/Q)



Q2 2025 Results Conference Call Agenda

17 July 2025



CEO Remarks	Renée Aguiar-Lucander CEO
Operational Update	Maria Törnsén COO, President US
Pipeline Update	Hitto Kaufmann Chief Scientific & Technology Officer
Financial Results	Evan Ballantyne Chief Financial Officer
Close and Q&A	**Renée Aguiar-Lucander** **CEO**

Hansa Leadership

Renée Aguiar-Lucander
CEO

Evan Ballantyne
CFO

Hitto Kaufmann, PhD
Chief Scientific & Technology Officer

Maria Törnsén
COO, President US

Hansa Biopharma contacts and key events

Contacts



Evan Ballantyne

Chief Financial Officer

Email: ir@hansabiopharma.com

Calendar and Events

2025

16 SEPT	Pareto 16th Annual Healthcare Conf, Stockholm
8 OCT	Sachs BEF 25th Annual Biotech in Europe Conf, Basel
23 OCT	Interim Report (January – September)
13 NOV	SEB Health Conf, Stockholm
18 NOV	Jefferies Biotech Conf, London
25 NOV	DNB Carnegie, Oslo


HANSA
BIOPHARMA